Garth Strohbehn
Clinical Assistant Professor of Internal Medicine
[email protected]

Available to mentor
Garth Strohbehn
Clinical Assistant Professor
  • About
  • Qualifications
  • Center Memberships
  • Recent Publications
    • About

    I am a medical oncologist and researcher focused on the interface of clinical research, health services research, and operations. My observational health services work re-evaluates cancer drug dosing and its impacts on finances and operations, patients' experience of cancer care, and environmental impact. My methods development work focuses on generating novel trial designs to test de-intensification hypotheses, and I maintain an active clinical trial portfolio. I have a special interest in the economics of cancer drug development from an industrial organization perspective. My academic home is VA Ann Arbor's Center for Clinical Management Research.

    Qualifications
    • Clinical Fellow, Medical Oncology
      University of Chicago Medical Center, Biological Sciences Division, 2021
    • Chief Medical Resident
      University of Michigan, Internal Medicine, 2018
    • Internship & Residency, Internal Medicine
      University of Michigan, Internal Medicine, 2017
    • MD
      Yale University School of Medicine, New Haven, 2014
    • MPhil
      Cambridge University, Cambridge, 2009
    • BS, Summa cum laude
      University of Iowa, Iowa City, 2008
    • BA, summa cum laude
      University of Iowa, Iowa City, 2008
    Center Memberships
    • Center Member
      Rogel Cancer Center
    • Center Member
      Institute for Healthcare Policy and Innovation
    Recent Publications See All Publications
    • Journal Article
      The tyranny of non-inferiority trials.
      Tannock IF, Buyse M, De Backer M, Earl H, Goldstein DA, Ratain MJ, Saltz LB, Sonke GS, Strohbehn GW. Lancet Oncol, 2024 Oct; 25 (10): e520 - e525. DOI:10.1016/S1470-2045(24)00218-3
      PMID: 39362263
    • Journal Article
      Optimizing the doses of cancer drugs after usual dose finding.
      Strohbehn GW, Stadler WM, Boonstra PS, Ratain MJ. Clin Trials, 2024 Jun; 21 (3): 340 - 349. DOI:10.1177/17407745231213882
      PMID: 38148731
    • Journal Article
      Targeted randomization dose optimization trials enable fractional dosing of scarce drugs.
      Boonstra PS, Tabarrok A, Strohbehn GW. PLoS One, 2023 18 (10): e0287511 DOI:10.1371/journal.pone.0287511
      PMID: 37903093
    • Journal Article
      Adopting Weight-Based Dosing With Pharmacy-Level Stewardship Strategies Could Reduce Cancer Drug Spending By Millions.
      Bryant AK, Chopra Z, Edwards DM, Whalley AS, Bazzell BG, Moeller JA, Kelley MJ, Fendrick AM, Kerr EA, Ramnath N, Green MD, Hofer TP, Strohbehn GW. Health Aff (Millwood), 2023 Jul; 42 (7): 946 - 955. DOI:10.1377/hlthaff.2023.00102
      PMID: 37406228
    • Journal Article
      US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?
      Strohbehn GW, Lichter AS, Ratain MJ. J Clin Oncol, 2023 May 10; 41 (14): 2488 - 2492. DOI:10.1200/JCO.22.02049
      PMID: 36780590
    • Journal Article
      Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation.
      Strohbehn GW, Holleman R, Burns J, Klamerus ML, Kelley MJ, Kerr EA, Ramnath N, Hofer TP. JAMA Oncol, 2022 Nov 1; 8 (11): 1663 - 1667. DOI:10.1001/jamaoncol.2022.4109
      PMID: 36136314
    • Presentation
      Dosing and Schedule Questions: Connecting Health Services Research and Therapeutic Clinical Trials
      Strohbehn G. 2024 Nov 14;
    • Journal Article
      Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study.
      Miller S, Jiang R, Schipper M, Fritsche LG, Strohbehn G, Wallace B, Brinzevich D, Falvello V, McMahon BH, Zamora-Resendiz R, Ramnath N, Dai X, Sankar K, Edwards DM, Allen SG, Yoo S, Crivelli S, Green MD, Bryant AK. Lancet Oncol, 2024 Nov 14; DOI:10.1016/S1470-2045(24)00528-X
      PMID: 39551068